Lv6
1860 积分 2021-10-22 加入
Phase 2 Study of Amivantamab Plus Lazertinib in Previously Treated Patients With EGFR-Mutant Lung Cancers With Brain and Leptomeningeal Metastases
6小时前
已完结
Ifebemtinib plus garsorasib as first-line treatment for KRASG12C-mutated non-small-cell lung cancer in China: a multicentre, single-arm expansion cohort from a phase 1b/2 trial
16天前
已完结
Consensus on the diagnosis and treatment of unresectable stage III driver gene-positive non-small cell lung cancer
26天前
已完结
Navigating controversies in stage III NSCLC: a multidisciplinary case discussion on evolving treatment paradigms
26天前
已完结
Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non–Small Cell Lung Cancer
26天前
已完结
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
1个月前
已完结
First-line immunotherapy in non-small cell lung cancer: how to select and where to go
1个月前
已完结
First-line serplulimab plus chemotherapy with or without HLX04 versus chemotherapy in locally advanced or metastatic non-squamous non-small-cell lung cancer (ASTRUM-002): a randomised, double-blind, multicentre phase 3 trial
1个月前
已完结
Selpercatinib in Early-Stage RET Fusion-Positive Non-Small-Cell Lung Cancer
2个月前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China
2个月前
已完结
皖公网安备34019202002308
